The fight against hypophosphatasia, a rare genetic disorder affecting bone mineralization, is seeing a concerning trend driving market growth. A recent analysis by Future Market Insights reveals the global Hypophospatasia Treatment Market is expected to reach approximately USD 26.27 million by 2033. This reflects a projected Compound Annual Growth Rate (CAGR) of 5.0% between 2023 and 2033.
Furthermore, factors such as increased government and non-profit initiatives in various countries to improve public awareness about rare diseases result in a gradual increase in the diagnosis rate of unusual diseases. As a result, important variables such as favourable reimbursement policies and government finance for treatment in industrialised countries are increasing the rate of acceptance of this therapy. As a result, these factors are expected to add to the market’s revenue share throughout the forecast period.
Request Your Sample Copy Now:https://www.futuremarketinsights.com/reports/sample/rep-gb-16229
Other factors that are expected to drive the market growth include an increase in the incidence of rare diseases globally, an increase in the demand for Hypophosphatasia Drugs to improve the treatment of rare diseases, and an increase in government spending on healthcare infrastructure, such as favourable reimbursement for HPP. Furthermore, the increased availability of HPP therapies and the increased use of HPP drugs influence the market’s revenue share.
Moreover, the focus on the importance of patient safety, the increase in the population, the growth of awareness, improved healthcare infrastructure, and less stringent guidelines for rare diseases positively affect the growth of the hypophosphatasia market. Also, advancements in the HPP therapy as well as government support for treatment extend profitable opportunities to the market players during the analysis period.
Key Takeaways from the Hypophosphatasia Treatment Market Study
- The global hypophosphatasia treatment market was valued at US$ 15.36 Million by 2022-end
- From 2018 to 2022, the market demand expanded at a CAGR of 2.6%
- By Type, the Odontohypophospatasia segment of the market constitutes the bulk of the market with a market share of 48%
- By Treatment Type, the Medication segment dominates the market with a share of 47%
- From 2023 to 2033, Hypophosphatasia Treatment sales are expected to flourish at a CAGR of 5.0%.
- By 2033, the market value of Hypophosphatasia Treatment is expected to reach US$ 26.27 Million.
“An upsurge in financial support to researchers for developing new innovative drugs for treatment of hypophospatasia, coupled with strong product pipeline are expected to fuel the hypophospatasia treatment market over the analysis period,” remarks an FMI analyst.
Hypophosphatasia Treatment Market Competitive Landscape
Prominent players in the hypophosphatasia treatment industry are Kirin Holdings Company, Vericel Corporation, Mereo BioPharma Group plc., Novartis AG, AM-Pharma B.V., Alexion, Bayer AG, Enobia Pharma, and Pfizer, Inc., among others.
Hypophosphatasia Treatment Market Recent Developments:
- In November 2022, Rallybio, together with its partner Exscientia, has been working toward the selection of a small molecule development candidate to advance into the clinic targeting ENPP1 for the treatment of patients with hypophosphatasia (HPP).
- Significant progress has been made to identify a lead compound and generate mouse in vivo biomarker evidence to support the modulation of on-target activity.
Through this collaboration with a leading global HPP expert, in vivo efficacy data is expected in the second half of 2023. Following those results, both companies expect to commence investigational new drug (IND)–enabling studies.
More Valuable Insights Available
Future Market Insights offers an unbiased analysis of the global Hypophosphatasia Treatment Industry, providing historical data for 2018 to 2022 and forecast statistics from 2023 to 2033.
To understand opportunities in the Hypophosphatasia Treatment Market, the market is segmented based on type, treatment type, and end-user, across seven major regions.
Craft Your Personalized Report Experience Now:
https://www.futuremarketinsights.com/customization-available/rep-gb-16229
Key Segments Covered in the Hypophosphatasia Treatment Industry Analysis
Hypophosphatasia Treatment Market by Type:
- Odontohypophospatasia
- Pseudohypophospatasia
Hypophosphatasia Treatment Market by Treatment Type:
- Medication
- Asfotase AlfaNon-steroidal Anti-inflammatory Drugs
- Calcitonin
- Strensiq
- Surgery
Hypophosphatasia Treatment Market by End User:
- Hospitals
- Pharmacies
- Others
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI is the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
